133642-20-3

Basic information

• Product Name: Benzoic acid, 4-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-, methyl ester
• CAS NO: 133642-20-3
• Molecular Formula: C14H22O3Si
• Molecular Weight: 266.412
• Mol File: 133642-20-3.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 4-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 4-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-, methyl ester(133642-20-3)
• EPA Substance Registry System: Benzoic acid, 4-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-, methyl ester(133642-20-3)

Safety Data

• Hazardous Substances Data: 133642-20-3(Hazardous Substances Data)

Upstream product

• 67-56-1 methanol 
• 90446-67-6 4-((tert-butyldimethylsilyl)oxy)benzoyl chloride 
• 19438-10-9 methyl 3-hydroxybenzoate 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 99-76-3 methyl 4-hydroxylbenzoate 

Downstream Products

• 32122-11-5 4-benzyloxy-benzoic acid methyl ester 
• 99-76-3 methyl 4-hydroxylbenzoate 
• 99-96-7 4-hydroxy-benzoic acid 
• 126781-91-7 methyl 4-{[tert-butyl(dimethyl)silyl]oxy}cyclohexanecarboxylate 
• 643094-45-5 4-{[tert-butyl(dimethyl)silyl]oxy}-N-methoxy-N-methyl benzamide 
• 1435893-01-8 2-(4-((tert-butyldimethylsilyl)oxy)phenyl)-4H-quinolizin-4-one 

Relevant articles and documents

Diversity Oriented Clicking (DOC): Divergent Synthesis of SuFExable Pharmacophores from 2-Substituted-Alkynyl-1-Sulfonyl Fluoride (SASF) Hubs

Diversity Oriented Clicking (DOC) is a unified click-approach for the modular synthesis of lead-like structures through application of the wide family of click transformations. DOC evolved from the concept of achieving “diversity with ease”, by combining classic C?C π-bond click chemistry with recent developments in connective SuFEx-technologies. We showcase 2-Substituted-Alkynyl-1-Sulfonyl Fluorides (SASFs) as a new class of connective hub in concert with a diverse selection of click-cycloaddition processes. Through the selective DOC of SASFs with a range of dipoles and cyclic dienes, we report a diverse click-library of 173 unique functional molecules in minimal synthetic steps. The SuFExable library comprises 10 discrete heterocyclic core structures derived from 1,3- and 1,5-dipoles; while reaction with cyclic dienes yields several three-dimensional bicyclic Diels–Alder adducts. Growing the library to 278 discrete compounds through late-stage modification was made possible through SuFEx click derivatization of the pendant sulfonyl fluoride group in 96 well-plates—demonstrating the versatility of the DOC approach for the rapid synthesis of diverse functional structures. Screening for function against MRSA (USA300) revealed several lead hits with improved activity over methicillin.

NOVEL COMPOUND HAVING ISOXAZOLE CORE AND PHARMACEUTICAL COMPOSITION FOR DIABETES CONTAINING THE SAME MOLECULAR SKELETONS

The purpose of the present invention is to provide novel compounds having isoxazole by central structure as a PPAR gamma selective ligand, a manufacturing method thereof, and a pharmaceutical composition for treating PPAR gamma-related diseases containing the novel compounds or pharmaceutically acceptable salt thereof. The compounds can be applied to treatment of PPAR gamma-related diseases, especially, diabetes as an effective medicine without side effects which an existing TZD-series diabetes medicine has.

Synthesis, electrochemistry and anticancer activity of novel ferrocenyl phenols prepared via azide-alkyne 1,3-cycloaddition reaction

A series of monophenols and diphenols containing the ferrocene-C triazolyl and ferrocene-Ntriazolyl bond were prepared in a cycloaddition reaction of ethynylferrocene with aryl and benzyl azides and in a reaction of azidoferrocene with phenylacetylenes, respectively. The anticancer activity of the prepared compounds against hormone-dependent (MCF-7) and hormone-independent (HCC38) breast cancer cell lines was studied. The investigated compounds exhibited moderate anticancer activity against hormone-independent (IC50 ～ 15-48 μM) cancer cell line and low activity against hormone-dependent cancer cell line (IC50 ～ 84-98 μM).